Gradalis

Executive Summary

Gradalis is a late-stage biotechnology company developing personalized cancer immunotherapies based on its proprietary Vigil platform. The Vigil platform is designed to train a patient's own immune system to recognize and attack tumor cells by engineering autologous tumor cells to express a GM-CSF and an shRNA targeting furin, thereby enhancing antigen presentation and inhibiting TGF-β immunosuppression. The company's lead program targets ovarian cancer, with additional trials in Ewing sarcoma and other solid tumors. Gradalis has demonstrated promising Phase 2 data showing improved recurrence-free survival in ovarian cancer patients with BRCA mutations. The company is well-positioned to address significant unmet needs in oncology, particularly for patients with limited treatment options. As a private firm, Gradalis relies on investor funding and strategic partnerships to advance its pipeline. Key upcoming milestones include pivotal data readouts and potential regulatory interactions that could de-risk the platform and drive valuation.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 ovarian cancer trial top-line data65% success
• Q2 2026FDA Fast Track or Rare Pediatric Disease designation for Ewing sarcoma70% success
• Q4 2026Series C financing or partnership deal50% success